trikafta sale continu cf rais narrow-
moat vertex fair valu estim
updat forecast estim apr
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim apr
price data may
rate updat may
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
vertex known discov incivek blockbust
hepat drug overshadow vertex robust cystic
fibrosi franchis megablockbust potenti approv
treatment kalydeco orkambi symdeko trikafta make
vertex elig treat cf popul assum
intern pediatr approv expect vertex
maintain domin posit cystic fibrosi given strong
efficaci therapi lengthi patent lack competit
develop pipelin candid rare indic
cystic fibrosi rare indic character progress
deadli declin lung function affect approxim
peopl world-wide sinc launch kalydeco captur
target patient popul less cf patient
specif genet mutat becom backbon
combin therapi includ orkambi symdeko trikafta
orkambi launch expand elig patient popul
ad cf patient homozyg mutat
uptak slower safeti profil symdeko
launch didnt come worri safeti contribut
million revenu first year target
popul orkambi plu trikafta tripl combin
therapi receiv approv octob significantli
grow compani address patient popul
think vertex comprehens approach alreadi shape
treatment cf earn firm domin posit
market world-wide chronic natur therapi limit
competit horizon heighten market attract
given posit market dynam think vertex cf
program could grow billion within forecast period
early-stag pipelin span sever rare diseas includ
beta-thalassemia sickle-cel diseas well
antitrypsin defici think cf franchis
provid ampl cash futur develop asset
other
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
discov develop small-molecul drug
treatment seriou diseas key drug kalydeco orkambi
symdeko trikafta cystic fibrosi vertex therapi remain
standard care global vertex pipelin also includ therapi
cancer pain inflammatori diseas influenza rare diseas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
trikafta sale continu cf rais
narrow-moat vertex fair valu estim apr
narrow-moat vertex report strong quarter cystic
fibrosi franchis rais guidanc vertex recent
launch trikafta blew visibl alpha
analyst expect first quarter contribut
million revenu perspect first quarter
last year vertex cystic fibrosi franchis earn
million launch tripl combin
substanti expand compani address patient
popul cystic fibrosi launch
success wide adopt major elig
patient alreadi treatment five
month market revis estim
faster-than-expect uptak increas
fair valu estim per share narrow-moat
total revenu billion last year
rel modest research develop spend
result oper incom million margin
manag increas widen guidanc
present sever uncertainti relat new
patient start given extra precaut physician
interact high-risk patient reimburs
drug unemploy rate climb govern
experi financi strain guid midpoint
billion feel conserv view light strong
first-quart result manag cite pull-
forward revenu patient stock medic
declin complianc time adher highest
patient first start medic explain
institut clinic econom review icer
privat independ organ led cost-
effect research publish report
suggest trikafta price substanti lower
recommend discount roughli
trikafta list price high price tag alway risk
rare-diseas drug believ payer recogn
transform therapi earn premium price
even icer recogn drug substanti efficaci
award highest rate categori
vertex reimburs agreement europ
symdeko orkambi alreadi includ trikafta pend
approv expect fairli rapid uptak europ even
negoti countri take place
lastli pleas hear one compani
candid antitrypsin defici
pois move ahead phase trial second half
year along alreadi phase vertex
two shot net rare diseas estim
effect aatd treatment could earn peak sale
billion given vertex progress rais
probabl approv opportun howev
anticip challeng patient enrol due
pandem slightli elong develop time
increas vertex fair valu estim
due stronger-than-expect uptak
trikafta lesser extent impact time
valu money sinc last updat valuat remain
heavili depend cystic fibrosi portfolio includ
trikafta tripl combin pois continu
solid growth throughout explicit forecast period
look ahead wait approv trikafta
europ model occur late histor
compani face pushback price negoti
reimburs certain european countri recent
model billion cystic fibrosi sale
driven trikafta homozyg
heterozyg patient vertex complet portfolio cystic
fibrosi therapi allow target cystic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
due strong posit cystic fibrosi off-set
vulner potenti competit bull case
model higher probabl approv vertex pipelin
includ gene therapi candid blockbust
potenti rare indic assum trikafta
gain share quickli heterozyg popul
scenario mid-cycle sale surpass billion
compani oper margin bull-cas
fair valu estim
bear case assum trikafta face competit
price headwind lower sale assumpt cf
scenario mid-cycle sale billion
oper margin approxim bear-cas fair
valu estim
throughout explicit
vertex portfolio patent-protect cystic fibrosi
first-mov statu rare indic signific
patient share believ like
vertex abl earn excess return next
symdeko trikafta disease-modifi drug
market portfolio make backbon cystic
fibrosi therapi support strong price power
intang asset key moat sourc vertex
compani benefit patent protect
cystic fibrosi therapi vertex abl build upon
intellectu properti roll better medicin
combin increasingli captur patient
kalydeco approv cf patient one copi
mutat quickli pick label expans
addit mutat age group expand
elig patient popul patient
 first approv orkambi
approv patient two copi
fibrosi patient global expect peak sale cystic
fibrosi billion
give compani pipelin asset
probabl approv due earli stage
develop compani target sever blockbust
opportun amount billion
sale opportun includ gene therapi
beta thalassemia sickl cell diseas well
antitrypsin defici also
expect compani continu fund research cystic
fibrosi develop next-gener therapi small
molecul corrector gene therapi
assum oper expens grow midsingl
digit throughout forecast vertex continu cystic
fibrosi commerci strategi push pipelin
clinic trial robust product sale expand
oper margin past compar
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
common mutat expand elig patient
popul significantli global
end symdeko approv target
patient popul orkambi help vertex captur
addit patient share due better efficaci final
trikafta approv expand
popul trikafta potenti approv
abroad pediatr patient think elig
patient popul reach roughli
cf patient
vertex strategi build upon kalydeco symdeko
orkambi doublet combin add cftr
corrector kalydeco cftr potenti trikafta
tripl combin build molecul symdeko
kalydeco layer new cftr corrector elexacaftor
trikafta deliv promis data rapidli achiev
regulatori approv octob us uniqu
mechan therapi addit molecul
result new efficaci therapi serv
competit advantag vertex entrench
therapi cystic fibrosi treatment lengthen
period patent protect mani pipelin competitor
studi candid combin one
vertex molecul illustr vertex posit
backbon treatment option
price power vertex cystic fibrosi portfolio
potenti contribut billion sale
compar billion
vertex face signific competit cystic
fibrosi market opinion galapago partnership
previous closest competitor
report lacklust phase result lead candid
illustr high bar efficaci vertex portfolio
led partner initi step away
trial acquir galapago cf pipelin
octob still unclear intent
candid see viabl threat
competitor proteostasi doublet
triplet well one candid combin
vertex therapi report disappoint data
first quarter sever year behind vertex
think vertex pipelin outsid cf contribut
narrow moat mani asset earli stage
develop howev substanti cash flow
think compani well posit target sever rare
diseas next decad like pipelin
focu rare indic approv treatment
option think clinic success diseas could
solidifi vertex moat line
cystic fibrosi rare chronic condit without
command strong price power mani patient start
treatment earli childhood continu lifetim
estim kalydeco vertex first cf therapi
list price monotherapi target
cf patient orkambi symdeko
doublet treat much larger portion cf patient
far behind six-figur price tag trikafta
list price launch reach exhibit
compani strong price power strong efficaci
believ vertex benefit posit moat trend
rate base recent approv promis pipelin
like support domin posit cystic
fibrosi compani demonstr lucr
develop strategi build upon kalydeco
doublet orkambi symdeko well trikafta
tripl combin next five year estim
compani could treat elig patient
patient share increas driven trikafta approv
 long patent life like expir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
lack close competit also support
posit trend rate give vertex room take tripl
combin across finish line thu significantli
expand elig patient popul includ
cystic fibrosi patient
given earli statu assign much weight
opportun yet howev outsid cf think
compani right track see approv new
rare indic next five year vertex pipelin
candid includ treatment antitrypsin
defici beta-thalassemia sickle-cel diseas
pipelin span multipl drug class includ small
molecul corrector cell therapi gene edit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ocyst fibrosi main driver vertex valuat
compani could fail diversifi
opric pressur could erod return given high
price tag vertex therapi
ogene-edit program could disrupt vertex hold
cystic fibrosi market
oth firm cystic fibrosi therapi pois
domin lucr market forese
futur base disease-modifi potenti
drug chronic use patient limit
lead drug candid mostli
discov in-hous lend credibl drug-
discoveri technolog potenti gener
overtex combin therapi lengthi patent
protect profit cystic fibrosi portfolio
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
believ vertex strong financi health given
robust cash flow gener low debt level
year-end vertex held billion cash
invest million debtlik leas
oblig vertex reach profit
cystic fibrosi portfolio continu expand launch
tripl combin therapi trikafta think
compani remain black oper
level throughout explicit
forecast throughout compani put cash use
build pipelin outsid cf includ
acquisit collabor agreeement on-going
intern develop expect vertex continu
use cash build diversifi rare-diseas
portfolio look beyond cystic fibrosi market
believ vertex merit medium uncertainti rate
concentr cystic fibrosi off-set domin
market posit lack competit compani
valuat driven cystic fibrosi franchis growth
larg depend trikafta commerci success
think lack close competit strong cash
gener medium term provid solid cushion
risk relianc cystic fibrosi histor firm
experienc reimburs challeng europ includ
unit kingdom franc think conflict
larg mitig vertex final receiv
reimburs england orkambi symkevi
four year orkambi approv assum
solid price power throughout forecast vertex
efficaci therapi risk price pressur
payer regul depress return despit vertex
competit cystic fibrosi competit cf still
fairli spars lucr market opportun could attract
rival vertex therapi disease-modifi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
correct underli genet mutat leav room
improv vertex next-gener
pipelin cf corrector gene edit compet gene
edit could disrupt compani success franchis
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
capit group growth amer comp
american fund growth fund amer
capit research manag compani
share
fund
share
fund
stewardship rate although compani leadership
team transit follow announc
jeffrey leiden step ceo take role
execut chairman
jeffrey leiden becam ceo chairman
experi includ role manag director claru
ventur special life scienc capit well
presid chief oper offic abbott
laboratori experi pharma shone
brought vertex cash-burn stage
emerg biotech larg lead biotech firm
expans franchis cystic fibrosi therapi
former chief medic offic dr reshma kewalramani
take ceo role april join vertex
kewalramani spent decad
believ well-suit lead vertex expand
diversifi pipelin includ two acquisit
privat biotechnolog compani present
edit duchenn muscular dystrophi million
plu mileston semma therapeut
human-deriv stem cell islet cure type diabet
million asset remain earli stage
develop like manag team focu
fill vertex pipelin ensur futur growth well
patent expir seriou competit relat
cf drug
rest manag team compos
pharma veteran adequ level experi
view previou cfo ian smith abruptli termin
earli person behavior detail
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
disclos reason believ
significantli weigh compani stewardship
histor controversi relat compens
practic impact stewardship rate current
team think manag compens
histor high although recent measur spur
sharehold vote curtail amount go forward
leiden total compens million
sever senior manag compens packag
million respons sharehold disapprov
drop million compani also
probe secur exchang commiss
seri larg insid stock sale posit clinic
news past year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
trikafta sale continu cf rais
narrow-moat vertex fair valu estim apr
narrow-moat vertex report strong quarter cystic
fibrosi franchis rais guidanc vertex recent
launch trikafta blew visibl alpha
analyst expect first quarter contribut
million revenu perspect first quarter
last year vertex cystic fibrosi franchis earn
million launch tripl combin
substanti expand compani address patient
popul cystic fibrosi launch
success wide adopt major elig
patient alreadi treatment five
month market revis estim
faster-than-expect uptak increas
fair valu estim per share narrow-moat
total revenu billion last year
rel modest research develop spend
result oper incom million margin
manag increas widen guidanc
present sever uncertainti relat new
patient start given extra precaut physician
interact high-risk patient reimburs
drug unemploy rate climb govern
experi financi strain guid midpoint
billion feel conserv view light strong
first-quart result manag cite pull-
forward revenu patient stock medic
declin complianc time adher highest
patient first start medic explain
look ahead wait approv trikafta
europ model occur late histor
compani face pushback price negoti
reimburs certain european countri recent
institut clinic econom review icer
privat independ organ led cost-
effect research publish report
suggest trikafta price substanti lower
recommend discount roughli
trikafta list price high price tag alway risk
rare-diseas drug believ payer recogn
transform therapi earn premium price
even icer recogn drug substanti efficaci
award highest rate categori
vertex reimburs agreement europ
symdeko orkambi alreadi includ trikafta pend
approv expect fairli rapid uptak europ even
negoti countri take place
lastli pleas hear one compani
candid antitrypsin defici
pois move ahead phase trial second half
year along alreadi phase vertex
two shot net rare diseas estim
effect aatd treatment could earn peak sale
billion given vertex progress rais
probabl approv opportun howev
anticip challeng patient enrol due
pandem slightli elong develop time
increas vertex fve strong promis
outlook cystic fibrosi beyond jan
expect mid- high single-digit increas
fair valu estim narrow-moat vertex follow
biotech strong fourth-quart result manag
guidanc compani lead posit cystic
fibrosi therapi basi narrow econom moat
rate cement ahead-of-schedul
approv trikafta octob trikafta launch
surpass expect fourth quarter partial
help launch-rel inventori build roughli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
million contribut million sale vertex
seen strong interest trikafta patient group
includ patient alreadi exist vertex therapi
full-year adjust oper incom nearli billion
last year total revenu
billion last year cf drug trikafta
symdeko drive top-lin growth fourth quarter
surpris see rapid rate convers
older vertex cf therapi kalydeco orkambi symdeko
trikafta plan adjust model account
faster-than-expect convers trikafta lift
sale estim substanti trikafta price
point rel vertex therapi
switch trikafta illustr drug attract profil
demonstr high bar futur competitor
includ eventu gener expect vertex
abl defend domin posit cf brand
gener competit thank long patent live
portfolio expertis indic continu
invest search next-gener therapi
look catalyst year look forward
see data vertex early-stag asset mark
compani key opportun pivot new diseas
area outsid cf anticip earli data
small molecul alpha-on antitrypsin defici
well addit data vertex crispr
therapeut gene therapi sickl cell diseas
beta thalassemia demonstr posit result
two patient late approv rare indic
high unmet need would solidifi vertex
competit posit narrow moat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
